lansoprazole has been researched along with Hypophosphatasia in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Hypophosphatasia: A genetic metabolic disorder resulting from serum and bone alkaline phosphatase deficiency leading to hypercalcemia, ethanolamine phosphatemia, and ethanolamine phosphaturia. Clinical manifestations include severe skeletal defects resembling vitamin D-resistant rickets, failure of the calvarium to calcify, dyspnea, cyanosis, vomiting, constipation, renal calcinosis, failure to thrive, disorders of movement, beading of the costochondral junction, and rachitic bone changes. (From Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Macrae, VE | 1 |
| Davey, MG | 1 |
| McTeir, L | 1 |
| Narisawa, S | 1 |
| Yadav, MC | 1 |
| Millan, JL | 1 |
| Farquharson, C | 1 |
1 other study available for lansoprazole and Hypophosphatasia
| Article | Year |
|---|---|
Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkaline Phosphatase; Animals; Blotting, Western; Calcifica | 2010 |